Genmab — December 2017
-
-
God morgen.
-
the Phase II Study in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: now recruiting https://clinicaltrials.gov/archive/NCT03236428/2017_12_21/changes
-
Analytiker Svend Bent og Børge Gert mener aktien kan falde yderligere men det er ikke uden risiko, især hvis vejret bliver over 11.6 grader i gennemsnit og storken mellemlander i Tønder. Åse, Gert Børges kone mener aktien vil lette hvis høsten af radiser når niveauet fra 1997. Svend Bents kone Gunhild mener derimod at folk glemmer at kigge på det fundamentale og at aktien er inde i en naturlig cyklus tilsat lidt short........God Jul til alle herinde!
-
haha
-
Glædelig herfra også og gode udsigter. Syntes faktisk det er særdeles betryggende med Dara/ Genmab øjne, at JJ nu er en af de to mest betydende spillere mht car-t. De vil helt sikkert spille Dara kortet rigtigt og har nu en endnu bedre hånd til at høre det.
-
Glædelig jul til alle her fra familiens butik i Rødovre Centrum og tusinde tak for fremragende debat og tone her på sitet.
-
Hi everyone, I'm curious if David Mygind would like to share his view on the overall Genmab situation, it has been a couple months since we heard from him right? Maybe he would like to come out of the shadow :). Have a nice evening and happy holidays!
-
@GlobalMacro - currently sailing the Caribbeans with unstable satellite internet. Will, nevertheless, try to voice my opinion by publishing something before New Year.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind